People: Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

21 Sep 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bienaime, Jean-Jacques 

Mr. Jean-Jacques Bienaime serves as Chairman of the Board, Chief Executive Officer of Biomarin Pharmaceutical Inc., He joined our Board in May 2005, at the same time that he became our Chief Executive Officer, and was named Chair of the Board in June 2015. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé currently serves on the board of Incyte Corporation, a public biotechnology company, as well as being a member of the boards of Biotechnology Innovation Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA), both industry trade associations. Mr. Bienaimé previously served on the boards of three public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, InterMune, Inc., from 2012 to 2014, and Vital Therapies, Inc., from 2013 to 2018. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

Basic Compensation

Total Annual Compensation, USD 1,200,380
Restricted Stock Award, USD 11,581,000
Long-Term Incentive Plans, USD --
All Other, USD 5,624,430
Fiscal Year Total, USD 18,405,900

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable 487,500 1,553,500.00
Exercised 117,000 8,365,070.00
Name Fiscal Year Total

Jean-Jacques Bienaime


Brian Mueller


Henry Fuchs


C. Greg Guyer


G. Eric Davis


Jeff Ajer

As Of  31 Dec 2019